肿瘤细胞治疗研究
ALL SOURCES
Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?
CAR-T 细胞治疗彻底改变了血液系统恶性肿瘤的治疗，提供了一种高度个体化且强效的免疫治疗手段。
Tumor-priming CD8(+) natural killer T-like cells as an efficient novel cell therapy for relapsed/refractory multiple myeloma.
TPNC 是一种通过肿瘤驱动的致敏产生的新型细胞毒性淋巴细胞产品。
CAR-Based Cell and Gene Therapies: Global Clinical Landscape and Emerging Therapeutic Strategies from ClinicalTrials.gov.
约 92% 的试验针对肿瘤，其中血液系统恶性肿瘤占 65% 的适应症；CD19 和 BCMA 是 III 期研究中的主要靶点。
Incidence of immune effector cell-associated neurotoxicity among patients treated with CAR T-cell therapy for hematologic malignancies: systematic rev
CAR T 细胞疗法相关 ICANS 的总体发生率为全级别 26.9%、高级别 10.5%。
共 4 条
MEMBER ACCOUNT
登录成功会直接打开下一页。
